TY - JOUR
T1 - Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue
AU - Canella, Claudia
AU - Mikolasek, Michael
AU - Rostock, Matthias
AU - Guckenberger, Matthias
AU - Jenewein, Josef
AU - Linka, Esther
AU - Six, Claudia
AU - Stoll, Sarah
AU - Stupp, Roger
AU - Witt, Claudia M.
N1 - Publisher Copyright:
© 2020 The Author(s).
PY - 2020/5/24
Y1 - 2020/5/24
N2 - Background: Although cancer-related fatigue (CRF) has gained increased attention in the past decade, therapy remains a challenge. Treatment programs are more likely to be effective if the needs and interests of the persons involved are well represented. This can be achieved by stakeholder engagement. In this paper, different key stakeholders' experiences and views on the feasibility of treating CRF in the context of supportive care in hospital environments are analyzed. Method: In a qualitative study with the aim of developing an integrative treatment program for CRF, a total of 22 stakeholders (6 medical oncologists, 5 nurses, 9 patients, 1 patient family member, 1 representative of the Swiss Cancer League) were interviewed either in a face-to-face (n = 12) or focus group setting (n = 2). For data analyses, the method of qualitative content analysis was used. Results: The stakeholders referred to different contextual factors when talking about the feasibility of treating CRF in the context of supportive care in hospital environments. These included: assessment, reporting and information; treatability; attitude; infrastructure, time-management, costs and affordability; and integrative approach. Conclusions: Key factors of a feasible treatment approach to CRF are a coherent, cost effective integrative treatment program facilitated by an interdisciplinary team of health care providers. Furthermore, the treatment approach should be patient orientated, adopting an individualized approach. The major challenges of making the integrative treatment program feasible for CRF are resources and interprofessional collaboration.
AB - Background: Although cancer-related fatigue (CRF) has gained increased attention in the past decade, therapy remains a challenge. Treatment programs are more likely to be effective if the needs and interests of the persons involved are well represented. This can be achieved by stakeholder engagement. In this paper, different key stakeholders' experiences and views on the feasibility of treating CRF in the context of supportive care in hospital environments are analyzed. Method: In a qualitative study with the aim of developing an integrative treatment program for CRF, a total of 22 stakeholders (6 medical oncologists, 5 nurses, 9 patients, 1 patient family member, 1 representative of the Swiss Cancer League) were interviewed either in a face-to-face (n = 12) or focus group setting (n = 2). For data analyses, the method of qualitative content analysis was used. Results: The stakeholders referred to different contextual factors when talking about the feasibility of treating CRF in the context of supportive care in hospital environments. These included: assessment, reporting and information; treatability; attitude; infrastructure, time-management, costs and affordability; and integrative approach. Conclusions: Key factors of a feasible treatment approach to CRF are a coherent, cost effective integrative treatment program facilitated by an interdisciplinary team of health care providers. Furthermore, the treatment approach should be patient orientated, adopting an individualized approach. The major challenges of making the integrative treatment program feasible for CRF are resources and interprofessional collaboration.
KW - Cancer-related fatigue
KW - Complementary medicine
KW - Feasibility
KW - Integrative treatment program
KW - Qualitative study
KW - Stakeholder engagement
UR - http://www.scopus.com/inward/record.url?scp=85085384899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085384899&partnerID=8YFLogxK
U2 - 10.1186/s12885-020-06858-6
DO - 10.1186/s12885-020-06858-6
M3 - Article
C2 - 32448184
AN - SCOPUS:85085384899
SN - 1471-2407
VL - 20
JO - BMC cancer
JF - BMC cancer
IS - 1
M1 - 458
ER -